Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01763931 · ClinicalTrials.gov registry record · Phase 2
DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT01763931: Completed Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT01763931 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01763931, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.
Primary Outcome
To assess whether two weeks of daily oral digoxin therapy, as compared to no study drug, reduces the expression of Hypoxia-inducible factor (HIF)-1α protein, measured by immunohistochemistry (IHC), in surgically resected breast cancer tissue obtained from women undergoing lumpectomy or mastectomy for invasive breast cancer.
Interventions
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-01 |
| Est. Completion | 2016-04-01 |
| Phase | Phase 2 |
What the finished NCT01763931 record still lists
NCT01763931 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 1 intervention - of which Digoxin is the first listed.
NCT01763931 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01763931 about?
NCT01763931 is a clinical study titled "DIG-HIF-1 Pharmacodynamic Trial in Newly Diagnosed Operable Breast Cancer". The purpose of this study is to learn what effects digoxin (DIG) may have on human breast cancer tissue.
What is the current status of trial NCT01763931?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2013-01. Estimated completion is 2016-04-01.
What interventions are being tested in trial NCT01763931?
The interventions under investigation include: Digoxin (DRUG).
Who is sponsoring clinical trial NCT01763931?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01763931's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia